The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Novartis
Stock and Other Ownership Interests - Novartis
Integrated biomarker analysis for 412 renal cell cancer (RCC) patients (pts) treated on the phase 3 COMPARZ trial: Correlating common mutation events in PBRM1 and BAP1 with angiogenesis expression signatures and outcomes on tyrosine kinase inhibitor (TKI) therapy.
 
Martin Henner Voss
Honoraria - Novartis
Consulting or Advisory Role - Alexion Pharmaceuticals; Calithera Biosciences; Exelixis; GlaxoSmithKline; Natera; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb; Genentech/Roche; Pfizer
Travel, Accommodations, Expenses - Novartis; Takeda
 
Fengshen Kuo
No Relationships to Disclose
 
David Chen
No Relationships to Disclose
 
Mahtab Marker
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Parul Patel
Employment - Novartis
Stock and Other Ownership Interests - Novartis
 
Almedina Redzematovic
No Relationships to Disclose
 
Nadeem Riaz
Honoraria - MedImmune
Research Funding - Bristol-Myers Squibb
 
Timothy A. Chan
Leadership - Bristol-Myers Squibb; Cancer Genetics; Illumina
Stock and Other Ownership Interests - Gritstone Bio
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Neoantigen discovery and genomic biomarkers for immunotherapy response
 
Toni K. Choueiri
Honoraria - NCCN; UpToDate
Consulting or Advisory Role - alligent; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Eisai; Exelixis; Foundation Medicine; GlaxoSmithKline; Merck; Novartis; Peloton Therapeutics; Pfizer; Prometheus; Roche/Genentech
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche/Genentech (Inst); TRACON Pharma (Inst)
Travel, Accommodations, Expenses - advisory boards/consultancy
 
James Hsieh
Honoraria - Chugai Pharma
Consulting or Advisory Role - Chugai Pharma; Eisai; Novartis
Research Funding - CGI; Eisai; Novartis; Pfizer
 
Robert J. Motzer
Consulting or Advisory Role - Eisai; Exelixis; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Eisai (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
A. Ari Hakimi
No Relationships to Disclose